GADD45B and hepatocellular carcinoma: Therefore, the expression of ACSL4 and GADD45B on HCC patients’ samples can potentially act as companion diagnostic biomarkers to facilitate the selection of patients with high ACSL4 and low GADD45B expression for treatment with aspirin and sorafenib.